A University of Plymouth spinout company is leading a £500,000 project to advance development of a vaccine to tackle bovine respiratory syncytial virus (BRSV).
With funding from Defra's Farming Innovation Programme, delivered in partnership with Innovate UK, The Vaccine Group (TVG) and the Animal and Plant Health Agency (APHA) will work together on a feasibility study focused on the vaccine dosing provided to young calves.
The work will determine the minimum dose required to provide effective protection against BRSV, a major viral contributor to bovine respiratory disease that is affecting cattle health, welfare and productivity worldwide.
It will also assess whether this protection can be achieved following a single vaccination, and builds directly on data from a recently completed Innovate UK Smart-funded project.
TVG was created to commercialise the work of
[STAFFMEMBER]
"> Professor Michael Jarvis, Professor in Virology & Immunology at the University and Technical Founder and Chief Scientific Officer of TVG, and operates from the [ARTICLE]
Derriford Research Facility - P
"> Derriford Research Facility on Plymouth Science Park.
/University Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
